SCHEMBL4229648

SCHEMBL4229648

CCOC(=O)C(CC(=O)c1ccc(-c2ccc(N)cc2)cc1)C(=O)OCC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.54
CYP1A2 P05177 2/20 0.54
CYP3A4 P08684 2/20 0.54
MAOA P21397 2/20 0.54
NPC1 O15118 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
TSHR P16473 2/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
PDE4D Q08499 1/20 0.42
ALDH1A1 P00352 3/20 0.42
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
RAB9A P51151 2/20 0.42
PRKCZ Q05513 1/20 0.42
GAA P10253 1/20 0.42
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7371528 0.85 L3MBTL1 (0.50) LMNANPC1MEN1KMT2ATSHR
SCHEMBL1748271 0.83 NPC1 (0.55) LMNACYP1A2CYP3A4MAOANPC1
SCHEMBL4233738 0.80 MAPT (0.54) LMNANPC1MEN1KMT2AALDH1A1
SCHEMBL1747948 0.80 KMT2A (0.51) LMNACYP1A2CYP3A4MAOANPC1
SCHEMBL28802831 0.80 L3MBTL1 (0.54) LMNACYP1A2CYP3A4NPC1MEN1
SCHEMBL4226890 0.80 KMT2A (0.53) LMNANPC1MEN1KMT2AALDH1A1
SCHEMBL928739 0.80 KMT2A (0.53) LMNACYP1A2CYP3A4MAOANPC1
SCHEMBL6014923 0.79 KMT2A (0.75) LMNACYP3A4NPC1MEN1KMT2A
SCHEMBL5068844 0.79 NPC1 (0.60) LMNACYP1A2CYP3A4MAOANPC1
SCHEMBL4226578 0.79 NPC1 (0.60) LMNACYP1A2CYP3A4MAOANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215780-A1 Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-27 US disclosed
US-20090215780-A1 Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-27 US disclosed
EP-1874317-A2 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY Bayer Pharmaceuticals Corporation (US) 2008-01-09 EP disclosed
WO-2006113919-A2 ARYL ALKYL ACID DERIVATIVES FOR AND USE THEREOF BAYER PHARMACEUTICALS CORPORATION (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215780-A1 Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity FABP4, GPR119, LIPC LMNA 844/4885CYP1A2 98/4885CYP3A4 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.